{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:47:04Z","timestamp":1790736424255,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-020-00541-1","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T15:12:31Z","timestamp":1609945951000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine Exposure"],"prefix":"10.1208","volume":"23","author":[{"given":"Sarah","family":"Badaoui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley M.","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A David","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John O.","family":"Miners","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Sorich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"key":"541_CR1","doi-asserted-by":"crossref","unstructured":"Lind JN, Interrante JD, Ailes EC, Gilboa SM, Khan S, Frey MT, et al. Maternal use of opioids during pregnancy and congenital malformations: a systematic review. Pediatrics. 2017;139(6).","DOI":"10.1542\/peds.2016-4131"},{"issue":"4","key":"541_CR2","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.1111\/1471-0528.15510","volume":"126","author":"D Bisson","year":"2019","unstructured":"Bisson D, Newell S, Laxton C. Antenatal and postnatal analgesia. BJOG Int J Obstet Gynaecol. 2019;126(4):e114\u2013e24.","journal-title":"BJOG Int J Obstet Gynaecol"},{"issue":"2","key":"541_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/clpt.2010.298","volume":"89","author":"P Zhao","year":"2011","unstructured":"Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther. 2011;89(2):259\u201367.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"541_CR4","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/bcp.13480","volume":"84","author":"TM Polasek","year":"2018","unstructured":"Polasek TM, Tucker GT, Sorich MJ, Wiese MD, Mohan T, Rostami-Hodjegan A, et al. Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation. Br J Clin Pharmacol. 2018;84(3):462\u201376.","journal-title":"Br J Clin Pharmacol"},{"key":"541_CR5","doi-asserted-by":"publisher","unstructured":"Rowland A, van Dyk M, Hopkins A, Mounzer R, Polasek T, Rostami A, et al. Physiologically based pharmacokinetic modeling to identify physiological and molecular characteristics driving variability in drug exposure. Clin Pharmacol Ther. 2018; https:\/\/doi.org\/10.1002\/cpt.1076.","DOI":"10.1002\/cpt.1076"},{"key":"541_CR6","doi-asserted-by":"crossref","unstructured":"Sorich M, Mulflib F, van Dyk M, Hopkins A, Polasek T, Marshall J, et al. Use of predictive analytics to identify physiological and molecular characteristics driving variability in axitinib exposure: a fresh approach to precision dosing in oncology. JCO Precis Oncol. 2018;Under Review.","DOI":"10.1002\/jcph.1377"},{"issue":"3","key":"541_CR7","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s40262-019-00822-9","volume":"59","author":"F Stader","year":"2020","unstructured":"Stader F, Kinvig H, Penny MA, Battegay M, Siccardi M, Marzolini C. Physiologically based pharmacokinetic modelling to identify pharmacokinetic parameters driving drug exposure changes in the elderly. Clin Pharmacokinet. 2020;59(3):383\u2013401.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"541_CR8","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/cpt.659","volume":"101","author":"AS Darwich","year":"2017","unstructured":"Darwich AS, Ogungbenro K, Vinks AA, Powell JR, Reny J-L, Marsousi N, et al. Why has model-informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future. Clin Pharmacol Ther. 2017;101(5):646\u201356.","journal-title":"Clin Pharmacol Ther"},{"key":"541_CR9","doi-asserted-by":"publisher","unstructured":"Darwich A, Ogungbenro K, Hatley O, Rostami-Hodjegan A. Role of pharmacokinetic modeling and simulation in precision dosing of anticancer drugs. Transl Cancer Res. 2017. https:\/\/doi.org\/10.21037\/tcr.2017.09.14.","DOI":"10.21037\/tcr.2017.09.14"},{"issue":"12","key":"541_CR10","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/psp4.12353","volume":"7","author":"RJ Keizer","year":"2018","unstructured":"Keizer RJ, ter Heine R, Frymoyer A, Lesko LJ, Mangat R, Goswami S. Model-informed precision dosing at the bedside: scientific challenges and opportunities. CPT Pharmacometrics Syst Pharmacol. 2018;7(12):785\u20137.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"541_CR11","first-page":"71","volume":"49","author":"T Polasek","year":"2015","unstructured":"Polasek T, Korprasertthaworn P, Mignone L, McLachlan A, Miners J, Tucker G, et al. Optimizing olanzapine dose: can modeling and simulation help? Aust NZ J Psychiatry. 2015;49:71.","journal-title":"Aust NZ J Psychiatry"},{"key":"541_CR12","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3389\/fphar.2016.00517","volume":"7","author":"A Rowland","year":"2016","unstructured":"Rowland A, Mangoni AA, Hopkins A, Sorich MJ, Rowland A. Optimized cocktail phenotyping study protocol using physiological based pharmacokinetic modeling and in silico assessment of metabolic drug\u2013drug interactions involving modafinil. Front Pharmacol. 2016;7:517.","journal-title":"Front Pharmacol"},{"issue":"7","key":"541_CR13","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/bdd.2081","volume":"38","author":"VK Jogiraju","year":"2017","unstructured":"Jogiraju VK, Avvari S, Gollen R, Taft DR. Application of physiologically based pharmacokinetic modeling to predict drug disposition in pregnant populations. Biopharm Drug Dispos. 2017;38(7):426\u201338.","journal-title":"Biopharm Drug Dispos"},{"issue":"6","key":"541_CR14","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/cpt.1084","volume":"104","author":"A Dallmann","year":"2018","unstructured":"Dallmann A, Pfister M, van den Anker J, Eissing T. Physiologically based pharmacokinetic modeling in pregnancy: a systematic review of published models. Clin Pharmacol Ther. 2018;104(6):1110\u201324.","journal-title":"Clin Pharmacol Ther"},{"key":"541_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/2193-9616-1-9","volume":"1","author":"M Jamei","year":"2013","unstructured":"Jamei M, Marciniak S, Edwards D, Wragg K, Feng K, Barnett A, et al. The Simcyp population based simulator: architecture, implementation, and quality assurance. In Silico Pharmacol. 2013;1:9.","journal-title":"In Silico Pharmacol"},{"issue":"2","key":"541_CR16","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1124\/jpet.110.167916","volume":"334","author":"P Raungrut","year":"2010","unstructured":"Raungrut P, Uchaipichat V, Elliot DJ, Janchawee B, Somogyi AA, Miners JO. In vitro\u2013in vivo extrapolation predicts drug\u2013drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans. J Pharmacol Exp Ther. 2010;334(2):609\u201318.","journal-title":"J Pharmacol Exp Ther"},{"key":"541_CR17","doi-asserted-by":"crossref","unstructured":"Gammal RS, Crews KR, Haidar CE, Hoffman JM, Baker DK, Barker PJ, et al. Pharmacogenetics for safe codeine use in sickle cell disease.(Report). Pediatrics. 2016;138(1).","DOI":"10.1542\/peds.2015-3479"},{"issue":"1","key":"541_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3109\/15360288.2014.997854","volume":"29","author":"OA Linares","year":"2015","unstructured":"Linares OA, Fudin J, Schiesser WE, Daly Linares AL, Boston RC. CYP2D6 phenotype-specific codeine population pharmacokinetics. J Pain Palliat Care Pharmacotherapy. 2015;29(1):4\u201315.","journal-title":"J Pain Palliat Care Pharmacotherapy"},{"issue":"12","key":"541_CR19","doi-asserted-by":"publisher","first-page":"761","DOI":"10.2165\/11318070-000000000-00000","volume":"48","author":"S-F Zhou","year":"2009","unstructured":"Zhou S-F. Polymorphism of human cytochrome P450 2D6 and its clinical significance. Clin Pharmacokinet. 2009;48(12):761\u2013804.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"541_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/BF03256429","volume":"16","author":"T Eissing","year":"2012","unstructured":"Eissing T, Lippert J, Willmann S. Pharmacogenomics of codeine, morphine, and morphine-6-glucuronide. Mol Diagn Ther. 2012;16(1):43\u201353.","journal-title":"Mol Diagn Ther"},{"issue":"4","key":"541_CR21","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/FTD.0b013e3182272b10","volume":"33","author":"MS Vandervaart","year":"2011","unstructured":"Vandervaart MS, Berger NH, Sistonen JJ, Madadi CP, Matok RI, Gijsen RV, et al. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study. Ther Drug Monit. 2011;33(4):425\u201332.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"541_CR22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40291-013-0028-5","volume":"17","author":"CF Samer","year":"2013","unstructured":"Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Applications of CYP450 testing in the clinical setting. Mol Diagn Ther. 2013;17(3):165\u201384.","journal-title":"Mol Diagn Ther"},{"issue":"4","key":"541_CR23","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/clpt.2013.254","volume":"95","author":"KR Crews","year":"2014","unstructured":"Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014;95(4):376\u201382.","journal-title":"Clin Pharmacol Ther"},{"key":"541_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1046\/j.1365-2362.33.s2.3.x","volume":"33","author":"I Cascorbi","year":"2003","unstructured":"Cascorbi I. Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication. Eur J Clin Investig. 2003;33:17\u201322.","journal-title":"Eur J Clin Investig"},{"issue":"4","key":"541_CR25","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1373\/49.4.542","volume":"49","author":"WH Chou","year":"2003","unstructured":"Chou WH, Yan FX, Robbins-Weilert DK, Ryder TB, Liu WW, Perbost C, et al. Comparison of two CYP2D6 genotyping methods and assessment of genotype\u2013phenotype relationships. Clin Chem. 2003;49(4):542\u201351.","journal-title":"Clin Chem"},{"issue":"4","key":"541_CR26","first-page":"257","volume":"7","author":"J Kirchheiner","year":"2006","unstructured":"Kirchheiner J, Schmidt H, Tzvetkov M, Keulen JT, L\u00f6tsch J, Roots I, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharm J. 2006;7(4):257.","journal-title":"Pharm J"},{"issue":"6","key":"541_CR27","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/j.1365-2125.1991.tb05585.x","volume":"31","author":"QY Yue","year":"1991","unstructured":"Yue QY, Hasselstr\u00f6m J, Svensson JO, S\u00e4we J. Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. Br J Clin Pharmacol. 1991;31(6):635\u201342.","journal-title":"Br J Clin Pharmacol"},{"issue":"27","key":"541_CR28","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1056\/NEJMoa041888","volume":"351","author":"Y Gasche","year":"2004","unstructured":"Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, et al. Codeine intoxication associated with Ultrarapid CYP2D6 metabolism. N Engl J Med. 2004;351(27):2827\u201331.","journal-title":"N Engl J Med"},{"issue":"4","key":"541_CR29","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1365-2125.1991.tb05550.x","volume":"31","author":"ZR Chen","year":"1991","unstructured":"Chen ZR, Somogyi AA, Reynolds G, Bochner F. Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. Br J Clin Pharmacol. 1991;31(4):381\u201390.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"541_CR30","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1046\/j.1442-200X.2001.01427.x","volume":"43","author":"TF Tong","year":"2001","unstructured":"Tong TF, Ng KK. Codeine ingestion and apparent life-threatening event in a neonate. Pediatr Int. 2001;43(5):517\u20138.","journal-title":"Pediatr Int"},{"issue":"4","key":"541_CR31","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1124\/dmd.112.050161","volume":"41","author":"AB Ke","year":"2013","unstructured":"Ke AB, Nallani SC, Zhao P, Rostami-Hodjegan A, Isoherranen N, Unadkat JD. A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. Drug Metab Dispos. 2013;41(4):801\u201313.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"541_CR32","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0009-9236(97)90118-1","volume":"62","author":"W Mia","year":"1997","unstructured":"Mia W, Elisabeth D, Gunilla F, Anders R. Induction of CYP2D6 in pregnancy*. Clin Pharmacol Ther. 1997;62(4):400.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"541_CR33","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/clpt.1985.114","volume":"37","author":"H Stellan","year":"1985","unstructured":"Stellan H, Bo L, Dun Ren P, Carl-Gunnar R, Anders R. Pregnancy-induced increase in metoprolol metabolism. Clin Pharmacol Ther. 1985;37(6):688.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"541_CR34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1124\/dmd.116.072249","volume":"45","author":"X Pan","year":"2017","unstructured":"Pan X, Ning M, Jeong H. Transcriptional regulation of CYP2D6 expression. Drug Metab Dispos. 2017;45(1):42\u20138.","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"541_CR35","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s00228-011-1069-5","volume":"67","author":"K Nezvalov\u00e1-Henriksen","year":"2011","unstructured":"Nezvalov\u00e1-Henriksen K, Spigset O, Nordeng H. Effects of codeine on pregnancy outcome: results from a large population-based cohort study. Eur J Clin Pharmacol. 2011;67(12):1253\u201361.","journal-title":"Eur J Clin Pharmacol"},{"issue":"22","key":"541_CR36","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1016\/S0024-3205(99)00503-2","volume":"65","author":"EA Kopecky","year":"1999","unstructured":"Kopecky EA, Simone C, Knie B, Koren G. Transfer of morphine across the human placenta and its interaction with naloxone. Life Sci. 1999;65(22):2359\u201371.","journal-title":"Life Sci"},{"issue":"8","key":"541_CR37","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1124\/dmd.108.021873","volume":"36","author":"JC Stevens","year":"2008","unstructured":"Stevens JC, Marsh SA, Zaya MJ, Regina KJ, Divakaran K, Le M, et al. Developmental changes in human liver CYP2D6 expression. Drug Metab Dispos. 2008;36(8):1587\u201393.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"541_CR38","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ejps.2009.12.002","volume":"39","author":"K Rowland Yeo","year":"2010","unstructured":"Rowland Yeo K, Jamei M, Yang J, Tucker GT, Rostami-Hodjegan A. Physiologically based mechanistic modelling to predict complex drug\u2013drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut \u2013 the effect of diltiazem on the time-course of exposure to triazolam. Eur J Pharm Sci. 2010;39(5):298\u2013309.","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"541_CR39","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/bdd.2510130607","volume":"13","author":"TB Vree","year":"1992","unstructured":"Vree TB, Wissen CPWGMV-V. Pharmacokinetics and metabolism of codeine in humans. Biopharm Drug Dispos. 1992;13(6):445\u201360.","journal-title":"Biopharm Drug Dispos"},{"issue":"2","key":"541_CR40","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/psp4.12144","volume":"6","author":"C Emoto","year":"2017","unstructured":"Emoto C, Fukuda T, Johnson TN, Neuhoff S, Sadhasivam S, Vinks AA. Characterization of contributing factors to variability in morphine clearance through PBPK modeling implemented with OCT1 transporter. CPT Pharmacometrics Syst Pharmacol. 2017;6(2):110\u20139.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"9","key":"541_CR41","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1124\/dmd.31.9.1086","volume":"31","author":"AN Stone","year":"2003","unstructured":"Stone AN, Mackenzie PI, Galetin A, Houston JB, Miners JO. Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Dispos. 2003;31(9):1086\u20139.","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"541_CR42","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1124\/dmd.31.9.1125","volume":"31","author":"MH Court","year":"2003","unstructured":"Court MH, Krishnaswamy S, Hao Q, Duan SX, Patten CJ, Von Moltke LL, et al. Evaluation of 3\u2032-azido-3\u2032-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos. 2003;31(9):1125\u201333.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"541_CR43","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/cpt.1699","volume":"107","author":"A Vildhede","year":"2020","unstructured":"Vildhede A, Kimoto E, Pelis RM, Rodrigues AD, Varma MVS. Quantitative proteomics and mechanistic modeling of transporter-mediated disposition in nonalcoholic fatty liver disease. Clin Pharmacol Ther. 2020;107(5):1128\u201337.","journal-title":"Clin Pharmacol Ther"},{"key":"541_CR44","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1472-6904-2-2","volume":"2","author":"S Ammon","year":"2002","unstructured":"Ammon S, Marx C, Behrens C, Hofmann U, M\u00fcrdter T, Griese E-U, et al. Diclofenac does not interact with codeine metabolism in vivo: a study in healthy volunteers. BMC Clin Pharmacol. 2002;2:2.","journal-title":"BMC Clin Pharmacol"},{"issue":"1","key":"541_CR45","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/cpt.1013","volume":"104","author":"M Shebley","year":"2018","unstructured":"Shebley M, Sandhu P, Emami Riedmaier A, Jamei M, Narayanan R, Patel A, et al. Physiologically based pharmacokinetic model qualification and reporting procedures for regulatory submissions: a consortium perspective. Clin Pharmacol Ther. 2018;104(1):88\u2013110.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"541_CR46","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1124\/dmd.105.007567","volume":"34","author":"M Garland","year":"2006","unstructured":"Garland M, Abildskov KM, Taylor S, Benzeroual K, Caspersen CS, Arroyo SE, et al. Fetal morphine metabolism and clearance are constant during late gestation. Drug Metab Dispos. 2006;34(4):636\u201346.","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"541_CR47","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1053\/j.semperi.2015.08.003","volume":"39","author":"M Feghali","year":"2015","unstructured":"Feghali M, Venkataramanan R, Caritis S. Pharmacokinetics of drugs in pregnancy. Semin Perinatol. 2015;39(7):512\u20139.","journal-title":"Semin Perinatol"},{"issue":"14","key":"541_CR48","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1056\/NEJM199610033351402","volume":"335","author":"CD Chambers","year":"1996","unstructured":"Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335(14):1010\u20135.","journal-title":"N Engl J Med"},{"issue":"19","key":"541_CR49","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1001\/jama.293.19.2372","volume":"293","author":"EL Moses-Kolko","year":"2005","unstructured":"Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. Jama. 2005;293(19):2372\u201383.","journal-title":"Jama."},{"issue":"2","key":"541_CR50","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5830\/CVJA-2016-021","volume":"27","author":"C Nelson-Piercy","year":"2016","unstructured":"Nelson-Piercy C. Physiological changes in pregnancy. Cardiovasc J Afr. 2016;27(2):89\u201394.","journal-title":"Cardiovasc J Afr"},{"issue":"1","key":"541_CR51","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/PL00007495","volume":"266","author":"A Nakai","year":"2002","unstructured":"Nakai A, Sekiya I, Oya A, Koshino T, Araki T. Assessment of the hepatic arterial and portal venous blood flows during pregnancy with Doppler ultrasonography. Arch Gynecol Obstet. 2002;266(1):25\u20139.","journal-title":"Arch Gynecol Obstet"},{"issue":"5","key":"541_CR52","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3109\/00365519209088376","volume":"52","author":"A Erman","year":"1992","unstructured":"Erman A, Neri A, Sharoni R, Rabinov M, Kaplan B, Rosenfeld JB, et al. Enhanced urinary albumin excretion after 35 weeks of gestation and during labour in normal pregnancy. Scand J Clin Lab Invest. 1992;52(5):409\u201313.","journal-title":"Scand J Clin Lab Invest"},{"issue":"5","key":"541_CR53","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/j.1365-2125.2012.04363.x","volume":"74","author":"L Gaohua","year":"2012","unstructured":"Gaohua L, Abduljalil K, Jamei M, Johnson TN, Rostami-Hodjegan A. A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4. Br J Clin Pharmacol. 2012;74(5):873\u201385.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"541_CR54","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1517\/17425255.3.4.557","volume":"3","author":"LS Hodge","year":"2007","unstructured":"Hodge LS, Tracy TS. Alterations in drug disposition during pregnancy: implications for drug therapy. Expert Opin Drug Metab Toxicol. 2007;3(4):557\u201371.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"541_CR55","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s002280050615","volume":"55","author":"WJ Tamminga","year":"1999","unstructured":"Tamminga WJ, Wemer J, Oosterhuis B, Weiling J, Wilffert B, de Leij LF, et al. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol. 1999;55(3):177\u201384.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"541_CR56","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.ajog.2004.08.030","volume":"192","author":"TS Tracy","year":"2005","unstructured":"Tracy TS, Venkataramanan R, Glover DD, Caritis SN. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. Am J Obstet Gynecol. 2005;192(2):633\u20139.","journal-title":"Am J Obstet Gynecol"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-020-00541-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-020-00541-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-020-00541-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T16:05:06Z","timestamp":1674835506000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-020-00541-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["541"],"URL":"https:\/\/doi.org\/10.1208\/s12248-020-00541-1","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,6]]},"assertion":[{"value":"27 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"A.D.R. is an employee and stockholder of Pfizer Inc. A.R. and M.J.S. are recipients of unrelated research support from Pfizer Inc. All authors declare that there are no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of Competing Interests"}}],"article-number":"15"}}